AUTHORS
Maria Perusini, MD, Msc, Flavia Patino2, Christopher Hillis, MD3, Pierre Laneuville, MD4, Salam Al-Kindi, MD5, Muna Al Rasheed, md6, Naeem Chaudhri, MD7, Muhned Alhumaid, MD, MBBS8, Delphine Rea, MD, PhD9, Hassan Sibai, MD, Msc, BSc10, Dennis Dong Hwan Kim, MD, PhD11
AFFILIATIONS
1 Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
2 Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
3 Juravinski Cancer Centre, Hamilton, Canada
4 McGill University Health Centre (MUHC), Montreal, Canada
5 Sultan Qaboos University, Muscat, Oman
6 Kuwait Cancer Control Center, Kuwait City, Kuwait
7 King Faisal Specialist Hospital & Research Centre Riyadh, Riyadh, Saudi Arabia
8 King Fahad Medical City, Riyadh, Saudi Arabia
9 Hôpital Saint-Louis, Paris, France
10 Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
11 Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada
ABSTRACT
Background:
Asciminib (ASC), a STAMP inhibitor that targets the ABL myristoyl pocket, has been approved after failure of ≥2 prior tyrosine kinase inhibitors (TKIs) based on the ASCEMBL trial, and as first-line therapy based on the ASC4FIRST trial. However, its role as a second-line treatment remains less well defined, particularly in the regions, where ASC has not been approved for earlier lines of therapy. We present real-world outcomes of patients who received ASC as second-line therapy across multiple countries.
Aims
To describe the clinical characteristics and outcomes of patients treated with ASC as second-line therapy.
Methods
We retrospectively analyzed 50 patients with chronic myeloid leukemia in chronic phase (CML-CP) treated with ASC as second-line therapy across five countries (Canada, Oman, Kuwait, Saudi Arabia, and France). The primary endpoints were the rates of major molecular response (MMR; BCR: ABL1 <0.1% IS) and MR4 (BCR: ABL1 <0.01% IS) at 12 months. Event-free survival (EFS) was defined as the time from ASC initiation to the earliest occurrence of any of the following events: (1) treatment failure according to ELN 2020 criteria; (2) confirmed loss of MMR on two consecutive assessments; (3) progression to accelerated phase (AP) or blast crisis (BC); (4) death from any cause; or (5) treatment discontinuation. Patients without an event were censored at the date of last follow-up.
Results:
The median age at diagnosis was 57 years (range, 44–65), and 27 patients (54%) were female. Sokal risk at diagnosis was low in 18 (37.5%), intermediate in 20 (41.7%), and high in 10 (20.8%) patients. Six patients had a history of cardiovascular disease.
First-line TKIs included dasatinib (n=16, 32%), nilotinib (n=19, 38%), and imatinib (n=15, 30%). Reasons for first-line TKI discontinuation were 1) resistance/progression (n=22; 47.7%) including resistance in chronic phase (n=12, 26%), suboptimal response with intolerance (n=7, 15.2%), progression (n=3, 6.5%); 2) intolerance with optimal molecular response (n=18, 39.1%), and 3) other reasons (n=6).
At ASC initiation, 10 patients (20%) had BCR: ABL1 ≥10% IS, whereas 16 (32%) were already in MMR or deeper response. Four patients harbored ABL1 kinase domain mutations (F486S, E255K, F359I, and one compound T315I/F359I mutation), and one patient had additional chromosomal abnormalities. The median ASC dose was 80 mg daily (range, 40-400 mg).
With a median follow-up of 512 days (IQR, 300-815), the cumulative 12-month MMR rate was 75.2% (95% CI [61.2–88.6]). Excluding patients already in MMR at ASC initiation, the cumulative 12-month MMR rate was 76.9% [59.8-90.5]. The cumulative 12-month MR4 rate was 43.6% [27.3–58.2]. Estimated EFS was 92.5% at 1 year and 88.1% at 2 years.
Patients with a baseline BCR: ABL1 level <10% tended to have higher 12-month MMR rates than those with BCR: ABL1 ≥10% (82.5% vs. 46.7%; P=0.073). A numerically higher 12-month MMR rate was observed in patients previously treated with imatinib (90.0%) compared with those treated with a second-generation TKI (64.7%); however, this difference was not statistically significant (P = 0.35). Likewise, cardiovascular risk factors did not affect MMR (75.0% vs. 66.7% at 12-month; p=0.88).
In multivariable Cox regression analysis, baseline BCR: ABL1 ≥10% was associated with a trend toward a lower likelihood of achieving MMR (HR 0.37, [0.14-1.04]; P=0.06), with borderline statistical significance.
At the last follow-up, six patients (12%) had discontinued ASC: three because of intolerance despite optimal response, one because of resistance in chronic phase, and two for other reasons (one during an attempt at treatment-free remission and one following progression to IDH-mutated acute myeloid leukemia without detectable BCR: ABL1).
Conclusion
As expected, ASC demonstrated high rates of molecular response, durable EFS, and tolerability as second-line therapy in this multinational real-world cohort. These findings support ASC as an effective second-line treatment option for patients with CML-CP, particularly in settings where access to ASC is available.
DISCLOSURES
Maria Perusini, MD, Msc: Novartis - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony)